Worldcoin appears to have sold 117M $WLD($38.7M) via OTC.Today, Worldcoin deposited 117M $WLD($38.7M) to #Binance and #FalconX, and then received 35M $USDC.https://t.co/k7ewApTkoO https://t.co/8ZR0OIvgTB ...

Imagine holding an asset for 15 years, watching it grow from pennies to hundreds of millions of dollars, and then suddenly deciding to sell everything at once. This week, the crypto market watched in absolute terror as a Satoshi era whale woke up from a 15-year slumber and dumped 9,500 Bitcoin worth over $670 million. Almost immediately, social media algorithms and mainstream financial outlets began screaming that the smartest money in the room was capitulating.If the original pioneers are abandoning ship, ...

Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points on Angelman Syndrome - **Aspire Study**: Focused on Angelman syndrome with 130 patients aged 4 to 17 years, primarily with full deletions, aiming for a primary endpoint of cognition based on the Bayley-4 scale [3][4] - **Clinical Significance**: The meaningful score difference (MSD) for cognition is set at +5, with a mean difference of 10.9 observed in actively treated patients compared to a maximum change of 1 in the control group [4][5][6] - **Statistical Power**: The Aspire study is powered for greater than 90% success based on the statistical modeling of natural history data [6] - **Patient Population**: The study enrolls only patients with full deletions to ensure a homogeneous and severe patient population, minimizing variability and placebo effects [10][11] - **Aurora Study**: A phase II/III study supporting the broader Angelman product, focusing on safety and efficacy across different genotypes [14][15] - **Regulatory Strategy**: The Aspire study will form the basis of the approval package, with the Aurora study providing additional safety and efficacy data [16] Insights on Multi-Domain Responder Index (MDRI) - **Endpoints**: The MDRI is a key secondary endpoint, with both cognition and MDRI being treated as primary endpoints in the study [20][22] - **MSD for MDRI**: The MSD for the MDRI is also set at five points, with individual domains having specific MSDs [28][29] Discussion on Setrusumab and Bone Mineral Density - **Setrusumab**: The drug shows benefits in vertebral fractures and bone mineral density, with a focus on translating these findings into functional outcomes [36][37] - **FDA Interaction**: The company is strategizing on how to approach the FDA for accelerated approval based on compelling vertebral data and the need for confirmatory studies [38][39] Sanfilippo Syndrome and Manufacturing Challenges - **FDA Feedback**: The FDA indicated that clinical data is sufficient for approval, but there are challenges related to manufacturing and additional paperwork [46][48] - **Validation Period**: A 2-week validation period is expected for resubmission, with no new clinical data required [49][52] Gene Therapy and Market Considerations - **Unmet Medical Need**: Sanfilippo syndrome represents a high unmet medical need, with a small patient population but significant potential for successful product launch [71][72] - **Pricing Strategy**: The company believes that accelerated approval will not significantly impact pricing, as the focus remains on the high unmet need [43] Future Outlook - **Clinical Data**: Anticipation of data readouts for various studies, including the potential for accelerated approval and the importance of patient-level understanding in ongoing trials [42][75] - **Launch Preparedness**: The company is prepared to launch therapies for Sanfilippo and GSDIa quickly, having prioritized these programs for resource allocation [74] Conclusion - Ultragenyx Pharmaceutical is actively advancing its pipeline for rare diseases, particularly focusing on Angelman syndrome and Sanfilippo syndrome, while navigating regulatory challenges and ensuring robust clinical data to support its therapies.

The OTC whale who bought large amounts of $BTC and $ETH at the start of the market downturn now seems to be giving up.He sold 23,500 $ETH($47.77M) to repay his loans 9 hours ago.Between Jan 8 and Feb 2, he bought 163,405 $ETH($440M) at $2,691 avg.Between Feb 2 and Feb 5, he bought 4,000 $cbBTC($296M) at $74,004 avg.He is now down as much as $135M.https://t.co/EAswJ2UuQZ ...

This OTC whale is aggressively buying the dip!Over the past 10 hours, he withdrew 2,500 $CBBTC($182.3M) from #Coinbase.During this market crash, he has accumulated 4,000 $CBBTC($296M) and 83,392 $ETH($204M) in total.https://t.co/mgPJYAIde1 https://t.co/3KP1lMmYy7Lookonchain (@lookonchain):This OTC whale continues to buy the dip!He bought another 33,000 $ETH($76.6M) and 250 $CBBTC($18.95M) today.https://t.co/I0txyh8k3n https://t.co/4GKW0cRpdV ...

This OTC whale continues to buy the dip!He bought another 33,000 $ETH($76.6M) and 250 $CBBTC($18.95M) today.https://t.co/I0txyh8k3n https://t.co/4GKW0cRpdVLookonchain (@lookonchain):Some whales are panic-selling, while others are bravely buying the dip.This OTC whale bought 30,392 $ETH($70.12M) and 500 $CBBTC($30.74M) over the past 10 hours.https://t.co/DZt7lpwYbK https://t.co/H576I2tnD4 ...

The market is falling, but the OTC whale (0xFB7) bought another 10,000 $ETH($28.97M) 7 hours ago.https://t.co/nPIYRppUzIhttps://t.co/3InBwCoBXT https://t.co/XAfqKCTMWyLookonchain (@lookonchain):The market is falling, but whales and institutions are buying $ETH.Trend Research borrowed 70M $USDT from Aave and bought 24,555 $ETH($75.5M), currently holding 651,310 $ETH($1.92B).OTC whale (0xFB7) bought 20,000 $ETH($58.8M) via #FalconX and #Wintermute. https://t.co/hGuO3OSs5P ...

RT BSCN (@BSCNews)🔍 @BINANCE NOW OPERATES UNDER A THREE-ENTITY MODEL IN ABU DHABI!Exchange, clearing, custody, and OTC — all separated, all supervised. Why this matters 👇https://t.co/7Znw7mRVXF ...

🔍 @BINANCE NOW OPERATES UNDER A THREE-ENTITY MODEL IN ABU DHABI!Exchange, clearing, custody, and OTC — all separated, all supervised. Why this matters 👇https://t.co/7Znw7mRVXF ...

Core Viewpoint - The news highlights the passing of Guan Ping, a prominent figure in the Chinese pharmaceutical industry, and acknowledges his significant contributions to the sector and various companies he worked with [2][4]. Group 1: Guan Ping's Contributions - Guan Ping was recognized as a senior professional manager in the Chinese pharmaceutical industry, earning accolades such as the "Top Ten Professional Managers" and "Top Ten Pharmaceutical Elites" [4]. - He played a pivotal role in the marketing of major OTC products like Calcium D and Bai Jia Hei, earning the title "Prince of OTC" for his achievements [4][5]. - His career began in 1988 at Xi'an Janssen, where he became the second local pharmaceutical representative, marking the start of his impactful journey in the industry [4]. Group 2: Career Milestones - A significant turning point in Guan Ping's career occurred in 1997 when he joined Wyeth as a regional marketing director, transitioning the company’s focus from hospital sales to the OTC retail market [4][5]. - Under his leadership, sales of Calcium D increased by nearly 20% in 1998, surpassing hospital sales in the retail market [5]. - In 2001, he joined Dongsheng Technology as a director and vice president, where he successfully revitalized the Bai Jia Hei brand, increasing its sales from over 2 million to more than 200 million [5][6]. Group 3: Innovative Strategies - Guan Ping introduced innovative marketing strategies, such as in-store competitions and training for pharmacy staff, which were unprecedented in the industry at the time [5]. - He recognized the challenges faced by pharmaceutical distributors due to shrinking profit margins and implemented a commission-based model in 2002 to enhance profitability for distributors [6]. - By 2004, the sales of the Dongsheng anti-cold family exceeded 50 million, with Bai Jia Hei achieving a record of 500 million [6].